Browsing Tag
Qualified Infectious Disease Product
2 posts
SCY-247 intravenous trial signals strategic shift in SCYNEXIS, Inc.’s antifungal pipeline
SCYNEXIS, Inc. advances IV SCY-247 into Phase 1. Discover what this signals for antifungal resistance and hospital markets.
Cosmo Technologies secures FDA approval for Aemcolo to treat travelers’ diarrhea
Cosmo Technologies has achieved a significant milestone with the recent approval from the U.S. Food and Drug Administration…